Close correlation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N4-behenoyl-1-β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia

Japanese Journal of Cancer Research

Volumn 92, Issue 9, 2001, Pages 975-982

  Yamauchi, Takahiro ^a   Kawai, Yasukazu ^a   Goto, Nobuyuki ^a   Kishi, Shinji ^a   Imamura, Shin ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Fukushima, Toshihiro ^a   Iwasaki, Hiromichi ^a   Tsutani, Hiroshi ^a   Masada, Mikio ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

ara C; ara CTP; AUC; BHAC; Clinical pharmacokinetics

Indexed keywords

CYTARABINE TRIPHOSPHATE; DRUG METABOLITE; ENOCITABINE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; PRODRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; AREA UNDER CURVE; BIOTRANSFORMATION; CYTARABINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTRACELLULAR FLUID; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PRODRUGS; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR STEM CELLS;

EID: 0034790923     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01188.x     Document Type: Article

References (38)

1. Chemotherapy in acute myelogenous leukemia: High dose, higher expectations?
2. What is the best induction regimen for acute myelogenous leukemia?
3. Current situation and perspective for treatment of acute myelogenous leukemia in adults
4. Metabolism and selective effects of 1-β-d-arabinofuranosylcytosine in L1210 and host tissues in vivo
5. The effect of 1-β-d-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells
6. Studies in mouse L-cells on the incorporation of 1-β-d-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-d-arabinofuranosylcytosine 5′-triphosphate
7. Metabolism of 1-β-d-arabinofuranosylcytosine in human leukemic cells
8. Detection of 1-β-d-arabinofuranosylcytosine incorporation into DNA in vivo
9. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells
10. Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C
11. 4-acyl-1-β-d-arabinofuranosylcytosine
12. 4-Behenoyl-1-β-d-arabinofuranosylcytosine as a potential new antitumor agent
13. 4-palmitoyl-1-β-d-arabinofuranosylcytosine in patients with hematologic malignancies
14. Clinical pharmacology of 1-β-d-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-d-arabinofuranosylcytosine
15. 4-behenoyl-1-β-d-arabinofuranosylcytosine
16. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length
17. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukemia in adults
18. 4-behenoyl-1-β-d-arabinofuranosylcytosine into DNA as 1-β-d-arabinofuranosylcytosine
19. Pharmacologically directed ara-C therapy for refractory leukemia
20. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia
21. Quantitation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-d-arabinofuranosylcytosine therapy
22. 4-behenoyl-1-β-d-arabinofuranosylcytosine
23. 4-behenoyl-1-β-d-arabinofuranosylcytosine
24. 4-behenoyl-1-β-d-arabinofuranosylcytosine in patients with acute leukemia
25. A new sensitive method for determination of intracellular 1-β-d-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo
26. Monitoring of intracellular 1-β-d-arabinofuranosylcytosine 5′-triphosphate in 1-β-d-arabinofuranosylcytosine therapy at low and conventional doses
27. A sensitive and specific radioimmunoassay for 1-β-d-arabino-furanosylcytosine
28. Clinical pharmacology of 1-β-d-arabinofuranosylcytosine
29. Leukocyte preparations from human blood: Evaluation of their morphologic and metabolic state
30. Statistical moments in pharmacokinetics
31. Relationship of 1-β-d-arabinofuranosylcytosine in plasma to 1-β-d-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-β-d-arabinofuranosylcytosine
32. 4-behenoyl-1-β-d-arabinofuranosylcytosine in acute leukemia patients
33. Saturation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-d-arabinofuranosylcytosine therapy
34. A model for the chemotherapy of acute leukemia with 1-β-d-arabinofuranosylcytosine
35. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukeimia
36. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy
37. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology
38. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: Visualization of chain elongation on a defined template